Bacteriophage therapy for infections in cancer patients

Weber‐Dąbrowska, Beata; Mulczyk, M; Górski, Andrzej

doi:10.1016/s1529-1049(01)00015-0

Cited by 71 publications

(51 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Even after the arrival of antibiotics, phage therapy continued to be extensively used to treat bacterial infections in eastern Europe and the former Soviet Union, and the Eliava Institute in Tbilisi (Georgia) was one of the crucial centers (11,77). The increasing problem of bacterial resistance to antibiotics revitalized interest in phage therapy, and many clinical trials in humans have been conducted (72,(78)(79)(80)(81)(82).…”

Section: Clinical Trials Of Phages In Human Patientsmentioning

confidence: 99%

Phage Therapy: a Step Forward in the Treatment of Pseudomonas aeruginosa Infections

Pires

Boas

Sillankorva

et al. 2015

J Virol

152

103

View full text Add to dashboard Cite

Antimicrobial resistance constitutes one of the major worldwide public health concerns. Bacteria are becoming resistant to the vast majority of antibiotics, and nowadays, a common infection can be fatal. To address this situation, the use of phages for the treatment of bacterial infections has been extensively studied as an alternative therapeutic strategy. Since Pseudomonas aeruginosa is one of the most common causes of health care-associated infections, many studies have reported the in vitro and in vivo antibacterial efficacy of phage therapy against this bacterium. This review collects data of all the P. aeruginosa phages sequenced to date, providing a better understanding about their biodiversity. This review further addresses the in vitro and in vivo results obtained by using phages to treat or prevent P. aeruginosa infections as well as the major hurdles associated with this therapy.

show abstract

Section: Clinical Trials Of Phages In Human Patientsmentioning

confidence: 99%

Phage Therapy: a Step Forward in the Treatment of Pseudomonas aeruginosa Infections

Pires

Boas

Sillankorva

et al. 2015

J Virol

152

103

View full text Add to dashboard Cite

show abstract

“…Most notably, phages replicate at the site of infection and are available in abundance where they are most required (58), and although no specific systematic studies have been carried out, no serious or irreversible side effects of phage therapy have yet been described. Phages have been used successfully to treat experimental infections, including BSIs and meningitis, in poultry and animals (2,57,59,60) and antimicrobial-resistant infections in humans (9,(67)(68)(69)(70). It is worth noting, however, that the majority of studies involving phage therapy in humans are mostly reports of the clinical treatment of infections that could not be treated successfully by other means and are not specific clinical trials with stringent negative controls.…”

mentioning

confidence: 99%

Using Bacteriophages To Reduce Formation of Catheter-Associated Biofilms byStaphylococcus epidermidis

Curtin

Donlan

2006

Antimicrob Agents Chemother

243

169

View full text Add to dashboard Cite

Use of indwelling catheters is often compromised as a result of biofilm formation. This study investigated if hydrogel-coated catheters pretreated with a coagulase-negative bacteriophage would reduce Staphylococcus epidermidis biofilm formation. Biofilms were developed on hydrogel-coated silicone catheters installed in a modified drip flow reactor. Catheter segments were pretreated with the lytic S. epidermidis bacteriophage 456 by exposing the catheter lumen to a 10-log-PFU/ml culture of the bacteriophage for 1 h at 37°C prior to biofilm formation. The untreated mean biofilm cell count was 7.01 ؎ 0.47 log CFU/cm 2 of catheter. Bacteriophage treatment with and without supplemental divalent cations resulted in log-CFU/cm 2 reductions of 4.47 (P < 0.0001) and 2.34 (P ‫؍‬ 0.001), respectively. Divalent cation supplementation without bacteriophage treatment provided a 0.67-log-CFU/cm 2 reduction (P ‫؍‬ 0.053). Treatment of hydrogel-coated silicone catheters with an S. epidermidis bacteriophage in an in vitro model system significantly reduced viable biofilm formation by S. epidermidis over a 24-h exposure period, suggesting the potential of bacteriophage for mitigating biofilm formation on indwelling catheters and reducing the incidence of catheter-related infections.

show abstract

“…Even after the discovery of antibiotics, phage therapy continued to be used in the former Soviet Union and Eastern Europe (7,9). Although many studies have reported on the potential and safety of phage therapy to treat patients with bacterial infections (23,92,94,(101)(102)(103)(104), the widespread use of phages in Western medicine is currently awaiting approval. In addition to the requirement for regulatory approval, other obstacles stand in the way of bringing phages into the clinical setting, including the development of bacterial resistance to phages, the narrow host ranges of phages, and concerns over the immunogenicity of phage therapy (44).…”

Section: Phage Engineering For Pathogen Control Natural Phage-based Amentioning

confidence: 99%

“…The self-replicating nature of phages and the availability of simple, rapid, and low-cost phage production processes are additional advantages for their use as antimicrobials (22). Phages have been used not only to treat and prevent human bacterial infections (9,(23)(24)(25) but also to control plant diseases (26)(27)(28)(29), detect pathogens (30)(31)(32)(33), and assess food safety (34)(35)(36)(37).…”

mentioning

confidence: 99%

Genetically Engineered Phages: a Review of Advances over the Last Decade

Pires

Cleto

Sillankorva

et al. 2016

Microbiol Mol Biol Rev

335

275

View full text Add to dashboard Cite

SUMMARYSoon after their discovery in the early 20th century, bacteriophages were recognized to have great potential as antimicrobial agents, a potential that has yet to be fully realized. The nascent field of phage therapy was adversely affected by inadequately controlled trials and the discovery of antibiotics. Although the study of phages as anti-infective agents slowed, phages played an important role in the development of molecular biology. In recent years, the increase in multidrug-resistant bacteria has renewed interest in the use of phages as antimicrobial agents. With the wide array of possibilities offered by genetic engineering, these bacterial viruses are being modified to precisely control and detect bacteria and to serve as new sources of antibacterials. In applications that go beyond their antimicrobial activity, phages are also being developed as vehicles for drug delivery and vaccines, as well as for the assembly of new materials. This review highlights advances in techniques used to engineer phages for all of these purposes and discusses existing challenges and opportunities for future work.

show abstract

Bacteriophage therapy for infections in cancer patients

Cited by 71 publications

References 6 publications

Phage Therapy: a Step Forward in the Treatment of Pseudomonas aeruginosa Infections

Phage Therapy: a Step Forward in the Treatment of Pseudomonas aeruginosa Infections

Using Bacteriophages To Reduce Formation of Catheter-Associated Biofilms byStaphylococcus epidermidis

Genetically Engineered Phages: a Review of Advances over the Last Decade

Contact Info

Product

Resources

About